Insights

2 quality ASX healthcare shares this leading broker rates highly

Pro Medicus Limited (ASX:PME) and this ASX healthcare share are highly rated and could be in the buy zone now…
The post 2 quality ASX healthcare shares this leading broker rates highly appeared first on The Motley Fool Australia. –

Thanks to a number of favourable long term tailwinds, the healthcare sector looks like it could be a great place to make buy and hold investments.

But which ASX healthcare shares should you be focusing on? Two that are highly rated are listed below. Here’s what you need to know about them:

Healius Ltd (ASX: HLS)

The first healthcare share to look at is Healius. It is one of Australia’s largest pathology and diagnostic imaging providers. It offers pathology and imaging services via various brands including Dorevitch Pathology, QML Pathology, Laverty Pathology, and Healthcare Imaging Services. The company also has a network of day hospitals and IVF clinics.

It has been performing very strongly in FY 2021. For example, during the first half it reported a 16% increase in revenue to $953.5 million and a 190% jump in net profit to $75.6 million. This was driven largely by its key pathology business, which reported a 22% increase in revenue to $711.4 million and significantly wider margins.

Pleasingly, its solid form has continued since the end of the first half, with Healius reporting solid growth during the third quarter.

Analysts at Goldman Sachs are positive on the company. They currently have a buy rating and $4.40 price target on its shares.

Pro Medicus Limited (ASX: PME)

Another healthcare share that is highly rated is Pro Medicus. It provides software that facilitates the clinical assessment of medical images. It has been growing at a very strong rate in recent years thanks to the rapidly growing demand for solutions that can process, transfer and store this type of data efficiently. This is particularly the case given that speed and accuracy is fundamentally linked to both treatment success and commercial incentives.

In light of this, it will come as no surprise to learn that Pro Medicus has been winning a number of major contracts over the last 12 months. One of which came earlier this month with the University of Vermont for its Visage platform. This contract is worth $18 million over a total of eight years.

Goldman Sachs is also bullish on the Pro Medicus. It currently has a buy rating and $53.80 price target on its shares. Commenting on recent contract wins, it said: “We believe the heightened rate of uptake underlines the increased value being ascribed by hospitals towards solutions that can provide additional flexibility/resilience; a theme we expect to persist.”

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

*Returns as of February 15th 2021

More reading

The 6-bagger ASX share that I now regret selling: fundie

Is the Pro Medicus (ASX:PME) share price a buy after its contract win?
Why GrainCorp, Pro Medicus, Redcape, & Treasury Wine are pushing higher

ASX 200 down 0.4%: Xero sinks, Telstra hit with $50m fine

Pro Medicus (ASX:PME) share price sinks despite new deal

The post 2 quality ASX healthcare shares this leading broker rates highly appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!